Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting

Annals of Pharmacotherapy

Volumn 35, Issue 9, 2001, Pages 1108-1113

  El Beyrouty, Claudine ^a   Spinler, Sarah A ^b  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Cilostazol; Coronary angioplasty; Intracoronary stenting

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; FIBRINOGEN RECEPTOR; TICLOPIDINE;

CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; CORONARY STENT; DEVICE; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; HEMATOLOGIC DISEASE; HUMAN; IMPLANT; PRIORITY JOURNAL; RESTENOSIS; REVIEW; THROMBOCYTE AGGREGATION; THROMBOSIS; VASODILATATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CORONARY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; FIBRINOLYTIC AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS; STENTS; TETRAZOLES;

EID: 0034830335     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10253     Document Type: Review

References (27)

1. Dramatic increase in use of coronary stents
2. Introduction to coronary artery stents and their pharmacotherapeutic management
3. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting
4. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease
5. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease
6. Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction
7. Antithrombotic therapy in patients undergoing percutaneous coronary intervention
8. A clinical trial comparing three antithrombotic drug regimens after coronary-artery stenting
9. Cilostazol has beneficial effects in treatment of intermittent claudication
10. Cilostazol
11. Effect of oral milrinone on mortality in severe congestive heart failure
12. Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation
13. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation
14. Usefulness of cilostazol versus ticlopidine in coronary artery stenting
15. Comparison of cilostazol versus ticlopidine therapy after stent implantation
16. Effects of cilostazol on angiographic restenosis after coronary stent placement
17. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis
18. Antiplatelet treatment with cilostazol after stent implantation
19. Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation
20. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy
21. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS)
22. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors
23. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial
24. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
25. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial